Herpes Cure Research in 2027: Vaccines, Gene Editing and New Drugs
HSV-1 and HSV-2 together infect more than 4 billion people. WHO estimates that about 3.8 billion people under 50 carry HSV-1 and roughly 520 million people...
Read Moreclinical trials
7 articles tagged with this topic
Pritelivir: The First New Herpes Drug in 20 Years Awaits FDA Decision
Pritelivir is an oral antiviral for herpes simplex virus (HSV-1 and HSV-2) that is under FDA review, with a decision expected in the fourth quarter of 2026. If...
Read More
Weekly Herpes Pill Update: Gilead Takes Over, GS-1179 Heads to Phase 2
A once-a-week pill for genital herpes is now in the hands of Gilead Sciences, the company behind most of the world's HIV drugs. Gilead licensed the program...
Read More
Herpes Viruses Against Cancer: FDA Approves a Second HSV-Based Melanoma Drug
Herpes simplex virus is best known for cold sores and genital herpes, but modified versions of it are now approved cancer drugs. On August 6, 2026, the FDA...
Read More
Herpes Cure Research in 2026: Vaccines, Gene Editing and New Drugs
Editorial note: This page is no longer updated. For the latest on pritelivir's FDA review, Gilead's weekly pill and gene editing trials, see our herpes cure...
Read MoreHerpes Vaccine Outlook From May 2025: Why 2026 Was Always Unlikely
Editorial note: This article was written in May 2025 and reflects the herpes vaccine landscape as it stood at that time. Since then, Moderna has stopped its...
Read More
Herpes Vaccine Candidates in 2025: Progress and Prospects
Editorial note: This article was written in 2025 and covers HSV vaccine candidates as they stood at that time. Since then, Moderna has stopped mRNA-1608...
Read More